Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Ascendi, officially known as Ascendi Pharma, is a prominent biopharmaceutical company headquartered in Denmark (DK). Founded in 2016, Ascendi has rapidly established itself in the pharmaceutical industry, focusing on the development of innovative therapies for rare diseases and unmet medical needs. With a strong operational presence across Europe and North America, the company is dedicated to advancing its pipeline of unique drug candidates.
Ascendi's core offerings include cutting-edge treatments that leverage advanced drug delivery systems, setting them apart in a competitive market. The company has achieved significant milestones, including successful clinical trials that underscore its commitment to improving patient outcomes. With a robust portfolio and a focus on scientific excellence, Ascendi Pharma is well-positioned as a leader in the biopharmaceutical landscape.
-14 vs industry average
Ascendi’s score of 26 is lower than 42% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
In 2025, Ascendi reported total emissions of approximately 721,000 kg CO2e, which includes 69,000 kg CO2e from Scope 1 and 652,000 kg CO2e from Scope 2 emissions (market-based). The previous year, 2024, saw total emissions of about 609,000 kg CO2e, with Scope 1 emissions at 62,000 kg CO2e and Scope 2 emissions (market-based) at 547,000 kg CO2e.
Ascendi has not disclosed any Scope 3 emissions data, indicating a potential area for future reporting and improvement. The company has not set specific reduction targets or climate pledges, which may reflect its current focus on establishing a baseline for emissions before committing to formal reduction initiatives.
As a company headquartered in Denmark (DK), Ascendi's emissions data is sourced directly from its own reporting, with no cascaded data from parent or related organizations. This positions Ascendi as an independent entity in its climate commitments and emissions reporting.
Access structured emission data, company specific factors and auditable source documents
2031
46.2% reduction in Scope 1
ASCENDIS commits to reduce absolute scope 1 and scope 2 GHG emissions 46.2% by 2031 from a 2025 base year
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more